Extracorporeal membrane oxygenation versus cardiopulmonary bypass during transcatheter aortic valve implantation:a meta-analysis of survival benefits
Since its approval by the Food and Drug Administration in 2011,transcatheter aortic valve implantation (TAVI) has rapidly evolved to become the preferred ultimate intervention for high-and intermediate-risk patients with severe symptomatic aortic stenosis.[1]This is due to its non-open-heart,minimally invasive and off-pump advantages.
更多- 翻译满意度评价:
- 提交
- 浏览:3
- 被引:0
- 下载:0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文